Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.00 USD
Change Today -0.09 / -2.91%
Volume 68.7K
EDAP On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

edap tms sa -adr (EDAP) Snapshot

Open
$3.06
Previous Close
$3.09
Day High
$3.09
Day Low
$2.90
52 Week High
07/8/14 - $6.05
52 Week Low
10/10/14 - $1.15
Market Cap
74.4M
Average Volume 10 Days
76.6K
EPS TTM
$-0.04
Shares Outstanding
24.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EDAP TMS SA -ADR (EDAP)

edap tms sa -adr (EDAP) Related Businessweek News

No Related Businessweek News Found

edap tms sa -adr (EDAP) Details

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It also offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. In addition, this division leases equipment; sells disposables and spare parts; and offers maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. It also offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of ESWL technology. In addition, this division is engages in the leasing of lithotripters; sale of disposables and spare parts; and provision of maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is based in Vaulx-en-Velin, France.

161 Employees
Last Reported Date: 04/2/15
Founded in 1979

edap tms sa -adr (EDAP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

edap tms sa -adr (EDAP) Key Developments

EDAP TMS SA Announces Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

EDAP TMS SA announced consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total net sales of EUR 6,455,000 against EUR 8,076,000 a year ago. Total revenues were EUR 6,477,000 against EUR 8,087,000 a year ago. Operating loss was EUR 1,030,000 against operating income of EUR 226,000 a year ago. Loss before taxes and minority interest was EUR 2,585,000 against EUR 526,000 a year ago. Net loss was EUR 2,638,000 or EUR 0.11 per basic and diluted share against EUR 570,000 or EUR 0.03 per basic and diluted share a year ago. For the year, the company reported total net sales of EUR 24,252,000 against EUR 24,065,000 a year ago. Total revenues were EUR 26,785,000 against EUR 24,080,000 a year ago. Operating loss was EUR 1,736,000 against EUR 2,755,000 a year ago. Loss before taxes and minority interest was EUR 396,000 against EUR 4,886,000 a year ago. Net loss was EUR 512,000 or EUR 0.02 per basic and diluted share against EUR 5,021,000 or EUR 0.24 per basic and diluted share a year ago. 2014 global revenue growth of 11% over 2013, driven by a 70% increase in revenues from the HIFU division.

EDAP TMS SA to Report Q4, 2014 Results on Apr 01, 2015

EDAP TMS SA announced that they will report Q4, 2014 results at 5:00 PM, Romance Standard Time on Apr 01, 2015

EDAP TMS SA, Q4 2014 Earnings Call, Apr 02, 2015

EDAP TMS SA, Q4 2014 Earnings Call, Apr 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EDAP:US $3.00 USD -0.09

EDAP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elbit Imaging Ltd 513.40 +2.10
Integra LifeSciences Holdings Corp $65.34 USD -0.14
Johnson & Johnson $100.35 USD +0.22
Stryker Corp $93.63 USD +0.23
View Industry Companies
 

Industry Analysis

EDAP

Industry Average

Valuation EDAP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDAP TMS SA -ADR, please visit www.edap-tms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.